{"acquisitions":[],"changes":[],"country":"US","description":"Incyclix Bio develops cancer therapies that target the cell-cycle machinery, led by INX-315, a selective CDK2 inhibitor in clinical trials. It is aimed at patients with cancers driven by abnormal proliferation, including CDK4/6-resistant breast cancer and CCNE1-amplified tumors. It draws on its founders' long history in CDK inhibitor development.","domain":"incyclixbio.com","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":54.666667,"lng":-1.75,"location":"Durham","multiples":[],"name":"Incyclix Bio","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":30000000,"connectionsAmong":[],"currency":"USD","date":"2025-10-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"incyclixbio-com-2025-10-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-22","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"incyclixbio-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-22","status":"attributed","url":null},{"fact":"existence","publisher":"incyclixbio.com","retrievedAt":"2026-05-22","status":"self-reported","url":"https://incyclixbio.com"},{"fact":"description","publisher":"incyclixbio.com","retrievedAt":"2026-05-22","status":"self-reported","url":"https://incyclixbio.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Nginx","WordPress","Typekit","Adobe Fonts","Yoast SEO 27.1.1","Google Analytics","Google Tag Manager","Slick","jQuery Migrate 3.4.1","DoubleClick Floodlight","Contact Form 7 6.1.5","WP Engine"],"totalRaisedUsd":50000000,"traction":[],"updatedAt":"2026-05-22","valuations":[]}